Cogen Jonathan D, DiBlasi Robert M, Gibson Ronald L, Debley Jason S
Division of Pulmonary and Sleep Medicine, Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle, Washington.
Respiratory Care Department, Seattle Children's Hospital and Research Institute, Seattle, Washington.
Pediatr Pulmonol. 2017 Aug;52(8):984-989. doi: 10.1002/ppul.23752. Epub 2017 Jul 3.
American Thoracic Society/European Respiratory Society (ATS/ERS) spirometry interpretation guidelines recommend ≥15 min between pre- and post-bronchodilator testing to evaluate for a bronchodilator response. We aimed to lengthen the time between albuterol administration and post-bronchodilator testing to adhere to ATS/ERS guidelines and evaluated if lengthening this wait time would increase the percentage of patients classified as bronchodilator responsive.
We compared the proportion of patients with a positive bronchodilator response between two groups of children with asthma, one group in which post-bronchodilator administration wait times were not standardized (pre-intervention) to another in which the wait time was extended to 15 min to adhere to ATS/ERS standards (post-intervention). We also determined the effect of this intervention on clinic appointment duration.
The analysis included 271 patients (145 pre-intervention and 126 post-intervention). The average wait time in the pre-intervention group was 6.5 ± 2.1 (mean ± SD) minutes compared to 16.2 ± 3.2 min (P < 0.001) post intervention, and clinic times increased from 83.0 ± 29.6 min to 91.7 ±22.5 min (P < 0.007) from the pre- to post-intervention group, respectively. In adjusted regression analysis, there was no significant change in FEV % predicted between the two groups.
In a busy pediatric pulmonary clinic, while we successfully lengthened time between albuterol administration and post-bronchodilator testing in the vast majority of patients, no difference was seen in the percentage of patients classified as bronchodilator responsive. Results from this study appear to question the ATS/ERS recommended 15 min post-bronchodilator administration wait time for children.
美国胸科学会/欧洲呼吸学会(ATS/ERS)肺量计解读指南建议,支气管扩张剂使用前和使用后的测试间隔≥15分钟,以评估支气管扩张剂反应。我们旨在延长沙丁胺醇给药与支气管扩张剂使用后测试之间的时间,以遵循ATS/ERS指南,并评估延长这段等待时间是否会增加被归类为支气管扩张剂反应性的患者比例。
我们比较了两组哮喘儿童中支气管扩张剂反应阳性的患者比例,一组支气管扩张剂使用后的等待时间未标准化(干预前),另一组等待时间延长至15分钟以符合ATS/ERS标准(干预后)。我们还确定了这种干预对门诊预约时长的影响。
分析纳入了271例患者(145例干预前和126例干预后)。干预前组的平均等待时间为6.5±2.1(均值±标准差)分钟,干预后为16.2±3.2分钟(P<0.001),门诊时间分别从干预前组的83.0±29.6分钟增加到干预后组的91.7±22.5分钟(P<0.007)。在调整回归分析中,两组间预测FEV%无显著变化。
在繁忙的儿科肺病门诊中,虽然我们成功延长了绝大多数患者沙丁胺醇给药与支气管扩张剂使用后测试之间的时间,但被归类为支气管扩张剂反应性的患者比例没有差异。本研究结果似乎对ATS/ERS建议的儿童支气管扩张剂使用后15分钟等待时间提出了质疑。